The New Trend of API Sourcing and Contract Manufacturing in China

For years China has been one of the main places for global drug companies to source APIs and pharma intermediates or contract out the manufacturing work of such compounds. Almost all world major pharma companies have sourced a variety of APIs and pharma intermediates in the country.

However, the fast growth of this Chinese industry experienced significant growth slowdown in the last one year or so. The financial crisis, which occurred coincidentally as the Chinese industry experienced the sharp decrease in API demand, is only one of the factors to blame. The quality incident in supply chain that involves Chinese companies has directly led to the apparent change in the raw material sourcing pattern of global drug companies in China.

Driven by the severe reality, a series of improvements have recently been made within the industry since the quality incident, including the revision of the current cGMP standard. Meanwhile, a number of foreign companies possessing specialty in quality control also rushed to China to help Chinese companies upgrade their quality control system and management. As a result of all these efforts, at present a fairly large number of drug companies from all over the world are still sourcing APIs in China or outsourcing the manufacturing work to the Chinese companies.

The report “The New Trend of API Sourcing and Contract Manufacturing in China” published by JZMed summarizes the latest developments in the Chinese API and CMO industry including the current industry and market size, service and manufacturing capability and capacity, the latest improvements made by both Chinese companies and government in product quality control and management, and the latest API sourcing pattern of global drug companies in China.

The report is a must-read book to all professionals in the industries of pharmaceutical, biotechnology, financial investment and outsourcing service that are interested in API supply and contract manufacturing in China or learning how the Chinese industry has been performing under the severe situation and how it will likely develop in the near future. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of pharmaceutical industry in their own countries.